The chronic disease landscape in 2025 has been shaped by groundbreaking cardiovascular trials, innovative AI-driven prediction models, comprehensive global burden assessments, and novel therapeutic approaches targeting inflammation and metabolism. Here are the five most impactful studies advancing our understanding and management of chronic disease.
1. Cardiovascular-Kidney-Metabolic Health Framework: A Paradigm Shift in Heart Failure Prevention
The Lancet Series on cardiovascular-kidney-metabolic (CKM) health represents a transformative approach to chronic disease prevention, published in September 2025. This comprehensive framework recognizes that cardiovascular diseases, chronic kidney disease, diabetes, and obesity are not separate entities but rather interconnected conditions sharing common pathophysiologic mechanisms.
Since 1990, the prevalence of leading modifiable heart failure risk factors—including overweight/obesity, hypertension, diabetes, and CKD—has increased sharply and shows evidence of acceleration. These risk factors frequently coexist, creating incremental lifetime risk of heart failure. The framework emphasizes life course-oriented prevention through longitudinal maintenance of CKM health, integrating novel therapeutic approaches including SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists that simultaneously improve multiple CKM parameters.
This paradigm shift moves beyond treating individual conditions to addressing the syndemic behavior of CKM disorders, offering shared opportunities for prevention and treatment across multiple chronic diseases.
2. Lepodisiran: Breakthrough in Cardiovascular Risk Reduction
The phase 2 trial of lepodisiran demonstrated a remarkable 94% reduction in lipoprotein(a), published in the New England Journal of Medicine in May 2025. This small interfering RNA therapy from Eli Lilly targets a genetic risk factor for cardiovascular disease that has historically been difficult to modify pharmacologically.
Elevated Lp(a) is linked to increased risk of myocardial infarction and stroke. The trial showed dose-dependent reductions in Lp(a) levels, with the highest doses achieving near-complete suppression. Injection-site reactions were generally mild and transient, occurring in 0-12% of participants depending on dose. Importantly, no serious adverse events were deemed related to lepodisiran, and liver enzyme elevations (occurring in 3% of treated participants) returned to baseline without intervention.
While these results represent biomarker changes rather than cardiovascular outcomes, phase 3 trials are underway to determine whether Lp(a) reduction translates to reduced cardiovascular events—potentially representing one of the most significant advances in cardiovascular prevention in recent years.
3. SOUL Trial: Expanding Cardiovascular Benefits of Oral Semaglutide
The SOUL trial demonstrated a 14% reduction in major adverse cardiovascular events (hazard ratio 0.86, 95% CI 0.77-0.96, P=0.006) with oral semaglutide in patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease. This landmark trial, presented at the American College of Cardiology meeting in 2025, reinforces how metabolic therapies originally developed for diabetes and obesity have become central to broad chronic disease management.
The trial’s significance extends beyond diabetes treatment, demonstrating that GLP-1 receptor agonists provide cardiovascular protection across the cardiometabolic spectrum. Combined with evidence from trials like STRIDE (showing semaglutide improved walking capacity by approximately 40 meters in patients with peripheral artery disease and type 2 diabetes), these findings underscore the need for more personalized care, especially in women and those with complex metabolic profiles.
4. Delphi-2M: AI-Powered Disease Prediction Decades in Advance
Researchers unveiled Delphi-2M, an advanced transformer-based AI model capable of predicting susceptibility to over 1,000 diseases decades in advance using health records from UK Biobank and Danish registries. Published in Nature in 2025, this represents a transformative step toward early identification and prevention of chronic diseases.
The model’s ability to integrate longitudinal health data and identify disease risk patterns years before clinical manifestation offers unprecedented opportunities for preventive intervention. This shifts the paradigm from reactive care—waiting until symptoms emerge—to proactive, personalized health maintenance. Complementary models like CURENet are achieving over 94% accuracy for predicting top chronic conditions by integrating multimodal EHR data more effectively than previous approaches.
These AI innovations are not futuristic concepts but are actively reshaping how clinicians detect and mitigate risk before disease onset, with potential applications across cardiovascular disease, diabetes, cancer, and neurodegenerative conditions.
5. Plant-Derived Anti-Inflammatory Compounds: Novel Approaches to Chronic Disease Prevention
A comprehensive 2025 review in the International Journal of Molecular Sciences synthesized evidence on plant-derived compounds’ anti-inflammatory properties and their role in preventing chronic diseases. Chronic inflammation is a key contributor to cardiovascular diseases, type 2 diabetes, neurodegenerative disorders, cancer, and obesity.
Polyphenols (quercetin, resveratrol), flavonoids (luteolin, apigenin), carotenoids (β-carotene, lycopene), and other phytochemicals (curcumin, gingerol) modulate inflammatory pathways including nuclear factor-κB and mitogen-activated protein kinase, reduce oxidative stress, and inhibit pro-inflammatory cytokines. These compounds also interact with gut microbiota, enhancing anti-inflammatory effects.
Evidence from animal studies and clinical trials demonstrates efficacy in reducing inflammation-related biomarkers and improving health outcomes. While challenges such as low bioavailability and optimal dosing require further investigation, advancing delivery technologies and personalized nutrition strategies may help translate these findings into practical applications for chronic disease prevention.
Key Implications for 2026 and Beyond
These five studies collectively point toward several transformative trends in chronic disease management:
- Integration over fragmentation: The CKM framework demonstrates that treating interconnected conditions together yields better outcomes than addressing them separately
- Precision prevention: AI-guided disease prediction enables intervention decades before disease manifestation
- Expanded therapeutic options: Medications crossing traditional indication boundaries (GLP-1 agonists, SGLT2 inhibitors) and novel targets (Lp(a) reduction) offer new prevention strategies
- Inflammation as a unifying target: Both pharmaceutical and nutraceutical approaches targeting chronic inflammation show promise across multiple disease states
- Personalized medicine: Combining genomics, AI, and longitudinal data accelerates the transition from reactive to proactive, individualized care
The field is rapidly moving toward earlier detection, more precise treatment, and prevention-focused care—setting the stage for continued advances in reducing the global burden of chronic disease.